Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04895410
Title Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab (TJ011133) With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors AbbVie
Indications

multiple myeloma

Therapies

TJ011133

Dexamethasone + TJ011133

Daratumumab + Dexamethasone + TJ011133

Carfilzomib + Dexamethasone + TJ011133

Dexamethasone + Pomalidomide + TJ011133

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | DEU


No variant requirements are available.